dexamethasone + pegylated liposomal doxorubicin + vincristine

This drug is a combination chemotherapy regimen consisting of dexamethasone, pegylated liposomal doxorubicin, and vincristine. It is primarily used in the treatment of multiple myeloma. Pegylated liposomal doxorubicin (PLD) is a formulation of doxorubicin encapsulated in pegylated liposomes, which prolongs circulation time and reduces cardiac toxicity compared to conventional doxorubicin. Vincristine is a vinca alkaloid that inhibits microtubule formation, disrupting mitosis in cancer cells. Dexamethasone is a synthetic glucocorticoid with anti-inflammatory and immunosuppressive properties that also induces apoptosis in certain hematologic malignancies. The combination aims to maximize antitumor efficacy while minimizing toxicity; studies have shown similar response rates to traditional regimens but with reduced severe neutropenia, sepsis risk, need for central venous access, growth-factor support, and alopecia—though hand-foot syndrome may be more common due to PLD[1][2][3]. The regimen can be administered on an outpatient basis due to the pharmacokinetic advantages of PLD[5].

Brand names

DOXIL + vincristine + dexamethasone

Other names

DVd regimen